Skip to main content

Marinus selling rare pediatric disease priority review voucher for $110M

The FDA awarded the Radnor company the lucrative voucher after its seizure drug Ztalmy was approved in March.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.